An EpiPen alternative is about to return to your local pharmacy

(By Ed Silverman for STAT)

The controversial EpiPen device is about to get still more competition.

A company that now has the rights to a rival product1 plans to start marketing its allergic-reaction device in the first half of 2017. However, Kaleo Pharma declined to disclose the pricing for its Auvi-Q, which had previously been sold by Sanofi before being withdrawn2 late last year over reports that the device delivered inaccurate doses. Continue reading article here……


Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or